Eva Szegezdi

Senior Lecturer in Biochemistry

National University of Ireland Galway

Ireland

Research Interests

Explore related searches

Professors in Ireland Professors in Immunology Immunology professors in Ireland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Eva Szegezdi is a Senior Lecturer in Biochemistry at the National University of Ireland Galway. Her research focuses on cell death and therapy, particularly the role of pore-forming proteins and natural killer cells in cancer treatment. She has published extensively on topics such as cell-cell interactions in hematopoietic niches, genetic risk evaluation in multiple myeloma patients, and the development of innovative cancer models and therapeutics.

Articles (15)

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (8)

Una FitzGerald

Senior Lecturer/Associate Professor of Biomedical Engineering

University of Galway

IRELAND

View details

Yen Choo

Associate Professor of Stem Cell Science and Regenerative Medicine

Lee Kong Chian School of Medicine

SINGAPORE

View details

Philippe Krebs

University of Bern

SWITZERLAND

View details

Dimitrios I. Zeugolis

University of Galway

IRELAND

View details

Alessandro Natoni

Sapienza University

ITALY

View details

Pilib Ó Broin

University of Galway

IRELAND

View details

Michael E. O'Dwyer

National University of Ireland Galway

IRELAND

View details

Nina Orfali

Trinity College Dublin, The University of Dublin

IRELAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Eva Szegezdi

Research Interests

Explore related searches

Contact this professor

About

Articles (15)

Disrupting membranes, controlling cell fate: the role of pore-forming proteins in cell death and therapy

Protocol for isolation and expansion of natural killer cells from human peripheral blood scalable for clinical applications.

Blood Cancer Network Ireland (BCNI) and National Cancer Registry Ireland (NCRI) collaboration: challenges and utility of an Enhanced Blood Cancer Outcomes Registry (EBCOR) pilot.

Natural killer cell-mimic nanoparticles can actively target and kill acute myeloid leukemia cells

Cell-cell interactome of the hematopoietic niche and its changes in acute myeloid leukemia

COMBINING SKY92 GENE EXPRESSION PROFILING AND IGH CLONALITY TO EVALUATE GENETIC RISK IN IRISH MULTIPLE MYELOMA PATIENTS

CCPlotR: an R package for the visualization of cell–cell interactions

TRAIL in the Treatment of Cancer: From Soluble Cytokine to Nanosystems.

Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor-natural killer cells.

Macromolecular crowding in the development of a three-dimensional organotypic human breast cancer model

CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment.

Inhibition of IRE1 alpha RNase activity sensitizes patient-derived acute myeloid leukaemia cells to proteasome inhibitors

Recreating the Bone Marrow Microenvironment to Model Leukemic Stem Cell Quiescence.

Hematopoietic versus leukemic stem cell quiescence: Challenges and therapeutic opportunities.

Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16Bcni-001/Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment

Collaborators (8)

Una FitzGerald

Yen Choo

Philippe Krebs

Dimitrios I. Zeugolis

Alessandro Natoni

Pilib Ó Broin

Michael E. O'Dwyer

Nina Orfali

Make your next move.